Literature DB >> 22430989

Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina.

Susana Córdoba1, Walter Vivot, Maria E Bosco-Borgeat, Constanza Taverna, Wanda Szusz, Omar Murisengo, Guillermina Isla, Graciela Davel.   

Abstract

The Mycology Department of the Instituto Nacional de Enfermedades Infecciosas "Dr. C. Malbrán", conducted the Second National Multicenter Survey on Fungemia due to Yeasts in Argentina. The aim was to obtain updated data of the frequency of the causative species encountered and their in vitro susceptibility to seven antifungal agents. Yeast species were identified by micromorphological and biochemical studies. Antifungal susceptibility testing was performed by the reference microdilution method E.Def 7.1 of the European Committee on Antibiotic Susceptibility Testing (EUCAST). A total of 461 viable yeasts were identified. The most frequent species were: Candida albicans (38.4 %), Candida parapsilosis (26 %), Candida tropicalis (15.4 %) and Candida glabrata (4.3 %). Other uncommon species, such as Candida viswanathii (0.6 %), Candida haemulonii (0.4 %), Candida inconspicua (0.2 %) and Candida fermentati (0.2 %) were also isolated. Among the Candida spp., 5.4 % and 1.6 % were resistant to fluconazole and voriconazole, respectively. Itraconazole and caspofungin were the most efficient agents against all Candida spp. tested (MIC < 1 mg/l). For anidulafungin, 21.6 % of C. parapsilosis showed a MIC value of 4 mg/l. Fluconazole was less active against 53.1 % of Cryptococcus neoformans (MIC > 8 mg/l), 75 % of Trichosporon spp., and 100 % of Rhodotorula spp., Geotrichum candidum, Saccharomyces cerevisiae. The global percentage of mortality was 20 %. The presence of uncommon species reinforces the need for performing continuous laboratory surveillance in order to monitor possible changes, not only in the epidemiological distribution of species, but also in the resistance to antifungal drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22430989     DOI: 10.1590/S0325-75412011000300003

Source DB:  PubMed          Journal:  Rev Argent Microbiol        ISSN: 0325-7541            Impact factor:   1.852


  17 in total

1.  Comparative analyses of classical phenotypic method and ribosomal RNA gene sequencing for identification of medically relevant Candida species.

Authors:  Constanza Giselle Taverna; María Eugenia Bosco-Borgeat; Omar Alejandro Murisengo; Graciela Davel; Mariana Côrtes Boité; Elisa Cupolillo; Cristina Elena Canteros
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-04       Impact factor: 2.743

2.  Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.

Authors:  Andrew M Borman; Julian Muller; Jo Walsh-Quantick; Adrien Szekely; Zoe Patterson; Michael D Palmer; Mark Fraser; Elizabeth M Johnson
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing.

Authors:  Maria Emilia Cattana; Catiana Dudiuk; Mariana Fernández; Florencia Rojas; Liliana Alegre; Susana Córdoba; Guillermo Garcia-Effron; Gustavo Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Antifungal Activity of Essential Oils Against Candida Species Isolated from Clinical Samples.

Authors:  S Córdoba; W Vivot; W Szusz; G Albo
Journal:  Mycopathologia       Date:  2019-07-29       Impact factor: 2.574

5.  Molecular Confirmation of the Relationship between Candida guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility.

Authors:  Catiana Dudiuk; Daiana Macedo; Florencia Leonardelli; Laura Theill; Matias S Cabeza; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Phenotypic and Molecular Evaluation of Echinocandin Susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis Strains Isolated during 30 Years in Argentina.

Authors:  Soraya Morales-López; Catiana Dudiuk; Walter Vivot; Wanda Szusz; Susana B Córdoba; Guillermo Garcia-Effron
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  First case report of bloodstream infection due to a Candida species closely related to the novel species Candida pseudorugosa.

Authors:  Constanza Giselle Taverna; Susana Córdoba; Guillermina Isla; Norma Fernández; Susana García; Mariana Mazza; Omar Alejandro Murisengo; Walter Vivot; Wanda Szusz; Graciela Davel; Iris Nora Tiraboschi; María Eugenia Bosco-Borgeat
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

8.  Phylogenetic relationships matter: antifungal susceptibility among clinically relevant yeasts.

Authors:  A F Schmalreck; M Lackner; K Becker; W Fegeler; V Czaika; H Ulmer; C Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

9.  Candida glabrata species complex prevalence and antifungal susceptibility testing in a culture collection: First description of Candida nivariensis in Argentina.

Authors:  Soraya Eugenia Morales-López; Constanza G Taverna; María Eugenia Bosco-Borgeat; Ivana Maldonado; Walter Vivot; Wanda Szusz; Guillermo Garcia-Effron; Susana B Córdoba
Journal:  Mycopathologia       Date:  2016-09-28       Impact factor: 2.574

10.  Epidemiology of candidemia in Latin America: a laboratory-based survey.

Authors:  Marcio Nucci; Flavio Queiroz-Telles; Tito Alvarado-Matute; Iris Nora Tiraboschi; Jorge Cortes; Jeannete Zurita; Manuel Guzman-Blanco; Maria Elena Santolaya; Luis Thompson; Jose Sifuentes-Osornio; Juan I Echevarria; Arnaldo L Colombo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.